The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets
暂无分享,去创建一个
Marco Beccuti | Francesca Cordero | Claudio Isella | Enzo Medico | Giorgio Corti | A. Bardelli | C. Isella | E. Medico | M. Buscarino | F. Di Nicolantonio | M. Mottolese | M. Linnebacher | F. Cordero | M. Beccuti | E. Valtorta | S. Veronese | A. Sartore-Bianchi | S. Siena | G. Picco | S. Lamba | M. Russo | Federica Di Nicolantonio | Mariangela Russo | Carlotta Cancelliere | Alberto Bardelli | Michael Linnebacher | Gabriele Picco | Andrea Sartore-Bianchi | Salvatore Siena | Silvio Veronese | Simona Lamba | Michela Buscarino | Emanuele Valtorta | Barbara Martinoglio | Marcella Mottolese | G. Corti | Carlotta Cancelliere | B. Martinoglio
[1] Li Li,et al. Exon Array Profiling Detects EML4-ALK Fusion in Breast, Colorectal, and Non–Small Cell Lung Cancers , 2009, Molecular Cancer Research.
[2] Armando Santoro,et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.
[3] Liam O'Connor,et al. Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer. , 2014, Cancer research.
[4] Limin Fu,et al. FLAME, a novel fuzzy clustering method for the analysis of DNA microarray data , 2007, BMC Bioinformatics.
[5] A. Chinnaiyan,et al. Outlier kinase expression by RNA sequencing as targets for precision therapy. , 2013, Cancer discovery.
[6] M. Santoro,et al. Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer. , 2013, The Journal of clinical endocrinology and metabolism.
[7] Sabine Tejpar,et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. , 2010, The Lancet. Oncology.
[8] Davide Corà,et al. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. , 2011, Cancer discovery.
[9] J. Mesirov,et al. GenePattern 2.0 , 2006, Nature Genetics.
[10] L. Mazzucchelli,et al. Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer , 2009, PloS one.
[11] Andrea Bertotti,et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. , 2013, Cancer discovery.
[12] R. Tibshirani,et al. Diagnosis of multiple cancer types by shrunken centroids of gene expression , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[13] Lewis C Cantley,et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy , 2013, Nature Medicine.
[14] H. Woo,et al. Integrative Analysis of Proteomic Signatures, Mutations, and Drug Responsiveness in the NCI 60 Cancer Cell Line Set , 2010, Molecular Cancer Therapeutics.
[15] T. Hunter,et al. The Protein Kinase Complement of the Human Genome , 2002, Science.
[16] Joshua C. Gilbert,et al. An Interactive Resource to Identify Cancer Genetic and Lineage Dependencies Targeted by Small Molecules , 2013, Cell.
[17] Lior Pachter,et al. Sequence Analysis , 2020, Definitions.
[18] W. Bodmer,et al. Cancer cell lines for drug discovery and development. , 2014, Cancer research.
[19] I. Cree,et al. Heterogeneity of chemosensitivity of colorectal adenocarcinoma determined by a modified ex vivo ATP-tumor chemosensitivity assay (ATP-TCA) , 2003, Anti-cancer drugs.
[20] Sabine Tejpar,et al. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. , 2011, The Lancet. Oncology.
[21] W. Bodmer,et al. Direct and immune mediated antibody targeting of ERBB receptors in a colorectal cancer cell-line panel , 2012, Proceedings of the National Academy of Sciences.
[22] D. Lambrechts,et al. Somatic Profiling of the Epidermal Growth Factor Receptor Pathway in Tumors from Patients with Advanced Colorectal Cancer Treated with Chemotherapy ± Cetuximab , 2013, Clinical Cancer Research.
[23] Yujin Hoshida,et al. Nearest Template Prediction: A Single-Sample-Based Flexible Class Prediction with Confidence Assessment , 2010, PloS one.
[24] Cole Trapnell,et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. , 2010, Nature biotechnology.
[25] Suzie K. Hight,et al. Immortalized epithelial cells derived from human colon biopsies express stem cell markers and differentiate in vitro. , 2010, Gastroenterology.
[26] Benjamin E. Gross,et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.
[27] Sabine Tejpar,et al. Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer , 2013, The Journal of pathology.
[28] Steven J. M. Jones,et al. Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.
[29] Adam A. Margolin,et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.
[30] I. Nagtegaal,et al. KRAS gene amplification in colorectal cancer and impact on response to EGFR‐targeted therapy , 2013, International journal of cancer.
[31] S. Ramaswamy,et al. Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.
[32] F. J. Ramos,et al. Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[33] K. Zatloukal,et al. Novel colon cancer cell lines leading to better understanding of the diversity of respective primary cancers , 2002, Oncogene.
[34] R. Tibshirani,et al. Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[35] Mira Ayadi,et al. Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic Value , 2013, PLoS medicine.
[36] Fang Fang,et al. FusionMap: detecting fusion genes from next-generation sequencing data at base-pair resolution , 2011, Bioinform..
[37] Benjamin E. Gross,et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.
[38] James D. Brenton,et al. Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of In Vitro Morphological Subtypes , 2014, PloS one.
[39] Andrea Lombardi Borgia,et al. The TPM3‐NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition , 2014, Molecular oncology.
[40] Pierre Laurent-Puig,et al. Mutations in the RAS‐MAPK, PI(3)K (phosphatidylinositol‐3‐OH kinase) signaling network correlate with poor survival in a population‐based series of colon cancers , 2008, International journal of cancer.
[41] R. Labianca,et al. Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer. , 2012, Journal of the National Cancer Institute.
[42] Alan Mackay,et al. Functional viability profiles of breast cancer. , 2011, Cancer discovery.
[43] Florian Markowetz,et al. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions , 2013, Nature Medicine.
[44] Andreas Schlicker,et al. Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition , 2013, International journal of cancer.
[45] B. Pan,et al. FGFR2 Is Amplified in the NCI-H716 Colorectal Cancer Cell Line and Is Required for Growth and Survival , 2014, PloS one.
[46] Jiang Qian,et al. TiGER: A database for tissue-specific gene expression and regulation , 2008, BMC Bioinformatics.